Herzuma® (trastuzumab-pkrb) – New and expanded indications
May 16, 2019 - The FDA approved Teva and Celltrion’s Herzuma (trastuzumab-pkrb), in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease, and for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature) breast cancer as a single agent following multi-modality anthracycline based therapy.
Top